Westlake Precision 出生コホート (WeBirth)
The Westlake Precision Birth Cohort (WeBirth) is a prospective cohort study among women with hyperglycemia during pregnancy and their offspring living in Hangzhou, China. The primary aim of this cohort is to characterize the continuous blood glucose response to dietary intake and physical activity among pregnant women with gestational diabetes mellitus (GDM) over 2 weeks, and to facilitate the development of personalized nutritional/lifestyle recommendation among these patients. Another aim of WeBirth is to investigate the association of dietary intake and physical activity together with continuous glucose change during pregnancy on the adverse birth outcomes including preterm birth, macrosomia and large-for-gestational-age birth. The secondary aim is to investigate the prospective associations of diet, physical activity and continuous glucose change over 2 weeks among the participants with long-term metabolic health of these women and their offspring.
調査の概要
状態
詳細な説明
In China, an alarming increase in the prevalence of GDM has been observed in the past decade. GDM is of concern because it is associated with several maternal and fetal medical disorders. Lifestyle changes such as diet and physical activity modifications are key for the prevention and treatment of GDM. However, the associations between dietary intake and physical activity and health outcomes for GDM women and their children remain unclear due to subjective measurements of diet and physical activity. Recently, the development of objective measurements such as food image identification and wearable activity trackers give an opportunity to gain more precise insight into these associations. In addition, for the same food and physical activity exposures, GDM women may have different blood glucose responses, but the nature of variation is currently poorly characterized. Therefore, the present WeBirth design incorporates three unique components, 1) objective measurement of physical activity during pregnancy using accelerometer; 2) measurement of dietary intake using both the Food Frequency Questionnaire and dietary records; 3) measurement of blood glucose levels over 2 weeks using continuous glucose monitors, with three standardized test meals during the 2 weeks. We will then follow up these women participants during and after this pregnancy, and also follow up their offspring.
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
Zhejiang
-
Hangzhou、Zhejiang、中国、310030
- Hangzhou Women's Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Women aged 18 years or older
- Women with GDM at 24-28 weeks of gestation
- Women intended to deliver at Hangzhou Women's Hospital
- Women intended to remain in Hangzhou with their child for ≥4 years
Exclusion Criteria:
● Women with cancer and other serious medical disorders
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:非ランダム化
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
他の:Standardized breakfast
Egg (50g), whole-wheat bread (35g), celery (30g), and dried bean curd (10g) |
Participants will be provided with a standardized breakfast on a morning of the days they wear a continuous glucose monitoring (CGM) device. |
|
他の:Standardized snack
Tomato (50g) and skim milk (200g) |
Participants will be provided with a standardized snack 2 hour after they have the standardized breakfast. |
|
他の:Standardized lunch
Rice (40g), oats (40g), shrimp (70g), lettuce (80g), lean pork (30g), carrot (10g), soaked auricularia auricula (20g), broccoli (80g), cucumber (10g), tomato egg drop soup (200g), salt (3g), and oil (8g) |
Participants will be provided with a standardized lunch 2 h after they have the standardized snack. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Continuous blood glucose change over 2 weeks
時間枠:Two weeks after enrollment
|
Glucose levels are assessed by continuous glucose monitoring over 2 weeks. |
Two weeks after enrollment
|
|
Adverse birth outcomes
時間枠:9-12 weeks after enrollment
|
Number of participants with adverse birth outcomes, such as, preterm birth, macrosomia and neonatal hypoglycemia. |
9-12 weeks after enrollment
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Body fat of the maternal participants
時間枠:6 months and 3 years after delivery
|
Body fat is assessed by the equipment of dual-emission X-ray absorptiometry (DXA) for the mothers. |
6 months and 3 years after delivery
|
|
Weight changes of the children during early childhood
時間枠:at delivery, age of 6 months, 1 year, 3 years and 6 years
|
Weight in kilograms |
at delivery, age of 6 months, 1 year, 3 years and 6 years
|
|
Number of participants developing type 2 diabetes
時間枠:6 years and 10 years after delivery
|
Risk of developing type 2 diabetes after the delivery of the women with gestational diabetes. |
6 years and 10 years after delivery
|
協力者と研究者
スポンサー
捜査官
- 主任研究者:Ju-Sheng Zheng, PhD、Westlake University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
その他の研究ID番号
- 20190701ZJS0007
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。